Table 1 Patients’ baseline characteristics

From: Efficacy and safety of levodopa–carbidopa intestinal gel from a study in Japanese, Taiwanese, and Korean advanced Parkinson’s disease patients

Characteristic

Number of patients (%)

Mean±s.d. [range]

Age, years

 

61.6±10.5 [45.0–83.0]

Sex

 Female

19 (61)

 

 Male

12 (39)

 

Ethnicity

 Japanese

23 (74)

 

 Taiwanese

4 (13)

 

 Korean

4 (13)

 

Duration of PD, years

 

12.4±5.1 [2.9–29.2]

Levodopa dose,a mg/day

30 (97)

1,011.7±629.7

‘Off’ time, hours/day

29 (94)

7.4±2.3 [3.0–11.6]

‘On’ time without troublesome dyskinesia, hours/day

29 (94)

7.5±2.5 [1.0–11.8]

‘On’ time with troublesome dyskinesia, hours/day

29 (94)

1.1±2.3 [0.0–9.2]

PDQ-39 summary index

30 (97)

35.5±13.8 [8–67]

UPDRS total score

30 (97)

27.7±15.5 [2–60]

UPDRS Part II score

30 (97)

9.4±6.6 [0–24]

UPDRS Part III score

30 (97)

16.5±9.7 [1–42]

  1. Abbreviations: PDQ, Parkinson’s Disease Questionnaire; UPDRS, Unified Parkinson’s Disease Rating Scale.
  2. N=31 except as noted. Daily hours of ‘off’ time and ‘on’ time with/without troublesome dyskinesia were recorded in the PD Symptom Diary, normalized to a 16 h waking day and averaged for the 3 days before the visit. ‘On’ time without troublesome dyskinesia is the sum of ‘on’ time without dyskinesia and ‘on’ time with non-troublesome dyskinesia.
  3. a Last full daily levodopa dose of levodopa–carbidopa immediate release tablets before the NJ procedure.
Back to article page